Clinical trials: Rivaroxaban
Prevention of Venous Thromboembolism, Congenital Heart Disease
An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure
This is an observational study in which the data from children with congenital heart disease will be collected and studied. These children will include those who are prescribed rivaroxaban by their doctors after a heart surgery…
- Conditions
- Prevention of Venous Thromboembolism, Congenital Heart Disease, Fontan Procedure, Children
- Trial name
- NCT06193863
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Japan
- Volunteers
- 61 people
- Sponsor
- Bayer
Kawasaki Disease, Coronary Artery Aneurysm
Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years
Based on an established Kawasaki disease cohort database, this prospective, single-center, single-arm, observational study will collect clinical data from children aged 2 years and older with giant coronary artery aneurysms after…
- Conditions
- Kawasaki Disease, Coronary Artery Aneurysm, Rivaroxaban, Anticoagulant Drugs
- Trial name
- NCT06993636
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Children's Hospital of Fudan University
Venous Thromboembolism, Children Under 2 Years
A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in children under 2 years old with venous thromboembolism (VTE).
- Trial name
- XAPAEDUS (NCT05900388)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care (SOC)
- Where
- 4 sites in Denmark, France and 2 more
- Volunteers
- 850 people
- Sponsor
- Bayer
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Phenprocoumon for the first…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947959
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Standard of care
- Where
- Germany
- Volunteers
- 665,533 people
- Sponsor
- Bayer
Coronary Artery Disease
Trained Immunity by Dual-pathway Inhibition in Coronary Artery Disease
Coronary artery disease (CAD) is a manifestation of systemic atherosclerosis for which single antiplatelet therapy (SAPT) is indicated if patients are stable.
- Trial name
- DUALCAD (NCT05210725)
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Cerebral Vein Thrombosis
Rivaroxaban vs. Warfarin in CVT Treatment
Cerebral venous thrombosis (CVT) is an uncommon venous-type of stroke tends to affect younger patients with somewhat different risk factors and much better outcome compared to arterial strokes.
- Trial name
- RWCVT (NCT04569279)
- Testing
- Rivaroxaban, Warfarin
- Where
- Syria
- Volunteers
- 71 people
- Sponsor
- Damascus University
Kawasaki Disease, Pilot Study
Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease
Based on a population pharmacokinetic model-based dose optimization study, a 15 mg-equivalent, age-, and bodyweight-adjusted dosing regimen for Chinese children with giant coronary artery aneurysms after Kawasaki disease was…
- Conditions
- Kawasaki Disease, Pilot Study, Coronary Artery Aneurysm, Rivaroxaban
- Trial name
- NCT06978439
- Testing
- Rivaroxaban (Xarelto)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Children's Hospital of Fudan University
Deep Vein Thrombosis, Pulmonary Embolism
Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients With Deep Vein Thrombosis and Pulmonary Embolism
To clarify the effectiveness and safety of the direct factor Xa inhibitor rivaroxaban in domestic clinical use for patients with deep vein thrombosis and pulmonary embolism
- Trial name
- NCT03091621
- Where
- Japan
- Volunteers
- 1,000 people
- Sponsor
- Nihon University
Venous Thrombosis, Pediatrics
Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects
The first study with rivaroxaban in pediatric subjects is a Phase I study, where the pharmacokinetic/pharmacodynamic (PK/PD) profile of rivaroxaban will be investigated to confirm that the exposure is comparable to adults.
- Trial name
- NCT01145859
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 36 sites in United States, Australia and 8 more
- Volunteers
- 59 people
- Sponsor
- Bayer
Venous Thromboembolism
EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis
The purpose of this study is to evaluate comparative efficacy and safety of rivaroxaban to standard of care in children with acute venous thromboembolism.
- Trial name
- EINSTEIN Jr (NCT02234843)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
- Where
- 109 sites in United States, Argentina and 26 more
- Volunteers
- 500 people
- Sponsor
- Bayer
Atrial Fibrillation
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
The purpose of the study is to compare the one-year and two-year risk of each of the following individual outcomes: Stroke and systemic embolism (SE), major bleeding and death between new users of anticoagulant for Stroke…
- Trial name
- BROTHER (NCT02864758)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonists, dabigatran (Pradaxa)
- Where
- France
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Cerebrosinovenous Thrombosis
Efficacy and Safety of Oral Rivaroxaban in Cerebrosinovenous Thrombosis
The study seeks to fill the gaps regarding safety and efficacy of rivaroxaban and standard anticoagulant. therefore the current study was planned with the aim to determine the safety and efficacy of rivaroxaban and standard…
- Trial name
- NCT07523347
- Testing
- Rivaroxaban, Warfarin
- Where
- Pakistan
- Volunteers
- 75 people
- Sponsor
- Muhammad Aamir Latif
Peripheral Artery Disease
DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease
Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis, causing patients to be at high risk of major adverse cardiovascular and limb events.
- Trial name
- DUAL-PAD (NCT04218656)
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet
- Where
- 2 sites in Netherlands
- Volunteers
- 159 people
- Sponsor
- Radboud University Medical Center
Intracardiac Thrombus
Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population
The goal of this observational study is to determine the efficacy of rivaroxaban treatment for intracardiac thrombi resolution in pediatric patients (< 16 years old) diagnosed with intracardiac thrombosis.
- Trial name
- NCT06371170
- Testing
- Rivaroxaban
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Azienda Ospedaliero, Universitaria Ospedali Riuniti
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947998
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Warfarin, Antiplatelet drugs
- Where
- United Kingdom
- Volunteers
- 50,299 people
- Sponsor
- Bayer
Thromboembolism
Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates
The purpose of this study is to find out whether rivaroxaban is safe and effective to use in children age newborn to less than 6 months and how long it stays in the body and how it is used in the body.
- Trial name
- Einstein Jr (NCT02564718)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 9 sites in Austria, France and 5 more
- Volunteers
- 10 people
- Sponsor
- Bayer
Brain Ischemia
Xarelto [SPAF] Post-marketing Surveillance in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Xarelto for SPAF.
- Trial name
- NCT01582737
- Testing
- Rivaroxaban(Xarelto, BAY59-7939)
- Where
- Japan
- Volunteers
- 11,310 people
- Sponsor
- Bayer
Acute Coronary Syndrome, Venous Thrombosis
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
This prospective cohort study will provide information about: Characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed standard of care for the first…
- Conditions
- Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation
- Trial name
- NCT02468102
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care drugs
- Where
- Sweden
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Venous Thromboembolism
Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)
The objective of this investigation is to assess safety and effectiveness of Xarelto under practice routine use in VTE secondary prevention after acute DVT, focusing on hemorrhagic-related AEs, recurrent venous thromboembolism…
- Trial name
- JPMS-XAR-VTE (NCT02558465)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Japan
- Volunteers
- 2,540 people
- Sponsor
- Bayer
Peripheral Arterial Disease, Venous Thormboembolism
VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization
Venous thromboembolism (VTE) has a high prevalence in patients with multiple comorbidities undergoing complex surgical procedures.
- Conditions
- Peripheral Arterial Disease, Venous Thormboembolism, Cardiovascular Diseases, Vascular Surgery Patient with PAD / Carotid Stenosis
- Trial name
- RESOLUTION (NCT06873321)
- Testing
- rivaroxaban 2.5 mg bid + aspirin 100 mg, clopidogrel 75 mg od for 3 months followed by aspirin 100 mg od for endovascular procedures or aspirin for open procedures
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- Science Valley Research Institute